Key points are not available for this paper at this time.
AbstractPurpose:Alterations in BRAF have been reported in 3-5% of prostate cancer, although further characterization is lacking. Here, we describe the nature of BRAF alterations in prostate cancer using a large cohort from commercially available tissue and liquid biopsies subjected to comprehensive genomic profiling (CGP). Experimental Design:Tissue and liquid biopsies from patients with prostate cancer were profiled using FoundationOne®CDx and FoundationOne®Liquid CDx CGP assays, respectively. Tissue biopsies from non-prostate cancer types were used for comparison (n=275,151). Genetic ancestry was predicted using a single nucleotide polymorphism-based approach. Results:Among 15,864 tissue biopsies, BRAF-activating alterations were detected in 520 cases (3.3%). The majority (463 samples, 2.9%) harbored Class II alterations, including BRAF rearrangements (243 samples, 1.5%), K601E (101 samples, 0.6%), and G469A (58 samples, 0.4%). BRAF-altered prostate cancers were enriched for CDK12 mutations (OR 1.87, 9.2% vs 5.2%, p=0.018), but depleted in TMPRSS2 fusions (OR 0.25, 11% vs 32%, p
Chehrazi‐Raffle et al. (Mon,) studied this question.